CAJ | 학술논문

新生儿乙型肝炎疫苗普种使我国的HBsAg流行率由1992年的9．75％降低至2006年的7．18％。但现有慢性HBV感染者仍然高达9000万，其中慢性乙型肝炎患者2000万～3000万。干扰素类及核苷和核苷酸类药物可有效抑制HBV复制、延缓疾病进展，但难以彻底治愈乙型肝炎。积极研发针对HBV复制过程特异靶点的直接抗病毒药物以及针对其免疫应答关键环节的免疫疗法，是实现乙型肝炎治愈目标的技术关键。中国学者在优化现有乙型肝炎治疗方案、探索新疗法等方面开展了卓有成效的工作。采用公共卫生策略来提高乙型肝炎预防和治疗的可及性和可负担性、扩大预防接种和规范化治疗的覆盖人群是降低乙型肝炎相关疾病负担和社会经济负担的最有效手段。
신생인을형간염역묘보충사아국적HBsAg류행솔유1992년적9．75％강저지2006년적7．18％。단현유만성HBV감염자잉연고체9000만，기중만성을형간염환자2000만～3000만。간우소류급핵감화핵감산류약물가유효억제HBV복제、연완질병진전，단난이철저치유을형간염。적겁연발침대HBV복제과정특이파점적직접항병독약물이급침대기면역응답관건배절적면역요법，시실현을형간염치유목표적기술관건。중국학자재우화현유을형간염치료방안、탐색신요법등방면개전료탁유성효적공작。채용공공위생책략래제고을형간염예방화치료적가급성화가부담성、확대예방접충화규범화치료적복개인군시강저을형간염상관질병부담화사회경제부담적최유효수단。
In China universal vaccination program against hepatitis B virus (HBV)in newborns has led to a dramatic decline in HBsAg prevalence from 9.75%in 1992 to 7.18%in 2006.However,it is estimated that there are still around 90 million patients with chronic HBV infection,including 20-30 million with chronic hepatitis B (CHB).As recommended therapies,interferons and nucleos(t)ide analogues can effectively suppress HBV replication and thereby halt the progression of liver disease.Unfortunately,the current standard of care could not cure CHB in most cases.Developing direct antiviral agents targeting the specific steps of HBV life cycle or immunotherapy against the key steps of immune response to HBV infection will ultimately enable us to cure CHB.Chinese hepatologists have published more and more papers on HBV prevention and management,with the aim of optimizing current modalities and exploring new therapies.Adopting the public health policy to improve the accessibility and affordability of preventive and therapeutic drugs and increase the coverage of vaccination and standardized treatment is the most effective means to reduce the enormous health and socioeconomic burden of HBV-related diseases.